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ABSTRACT 
The pUfPose of this study was to examine the influence of 
androstenedione supplementation on plasma testosterone, 
cortisol, and cholesterol, mean arterial pressure (MAP), body 
weight, organ weights, and bone mineral density (BMD) in 
female rats. At age 10 weeks, an initial BMD measure was 
made. Rats in the andro group (n = 13) received implants 
designed to deliver 1 J.lg androstenedione per gram body wt per 
day. Rats in the control group (n = 13) received similar 
implants containing dextrose. After 8 weeks an arterial 
catheter was surgically implanted. MAP was measured for 30 
minutes during home cage rest and a blood sample was taken 
for measurement of plasma cholesterol and testosterone. The 
next day animals were exposed to a novel stress (immersion in 
shoulder-deep, 37 ·C water) for 15 minutes. MAP was mea-
sured before, during, and after the stress, and blood samples 
were taken for measurement of plasma cortisol. Animals were 
then euthanized and a final BMD measurement was made. 
The heart, liver, kidneys, adrenal glands, and ovaries were 
excised and weighed. Plasma cholesterol was significantly 
lower in the andro group, but there were no differences in MAP, 
plasma testosterone, plasma cortisol, body weights, organ 
weights, or BMD between groups. 
t t t 
Androstenedione is one of many intermediate com-
pounds in steroid biosynthesis in the adrenal glands and 
the gonads. Cholesterol, the precursor for all steroid 
hormones, is converted first into 20 a-hydroxycholesterol 
by 20 a-hydroxylase and then into pregnenolone by 
desmolase. Pregnenolone can enter various biochemical 
pathways, resulting in the synthesis of mineralocorti-
coids (e.g., aldosterone), glucocorticoids (e.g., cortisol), 
androgens (e.g., testosterone), and estrogens (e.g., estra-
diol-17P). Testosterone may be metabolized in the liver 
to form 2a-, 16a-, and 6p-hydroxytestosterone, andros-
tenedione, and 16a-hydroxyandrostenedione (Sugiyama 
et al. 1994), and both testosterone and androstenedione 
may be aromatized to estrogens or reduced to 
17 
dihydrotestosterone in peripheral tissues (Longcope 
1996). In females, androstenedione is produced by the 
theca calls of the corpus luteum, and under these cir-
cumstances it is rapidly converted to estrogen and/or 
progesterone. The production of androgens by theca 
cells appears to be regulated by insulin and insulin-like 
growth factors, explaining the association between 
hyperinsulinaemia and hyperandrogenism observed in 
women with polycystic ovarian syndrome (Lanzone et al. 
1994, Nahum et al. 1995). 
Examination of the influence of supplemental an-
drostenedione on plasma levels of testosterone and 
changes in lean muscle mass and muscle strength have 
primarily focused on males. A single 100 mg dose of 
androstenedione failed to increase serum testosterone 
concentration in males, and long term (8-12 weeks) 
treatment with androstenedione did not enhance lean 
body mass or muscle strength in males participating in 
resistance training (King et al. 1999, Wallace et al. 
1999). Ingestion of a single 100 mg dose of andro-
stenedione in two healthy women, however, resulted in 
4- and 7-fold increases in blood testosterone concentra-
tion (Mahesh and Greenblatt 1962), but information 
about long term treatment with androstenedione on 
lean body mass or muscle strength in females is lacking. 
The adverse effects oflong term anabolic steroid use 
(and abuse) are well known and include infertility, 
atrophy of the gonads, male pattern baldness in both 
sexes, decrease in body fat in females, short stature 
(when the steroid is taken during periods of growth), left 
ventricular hypertrophy, and liver tumors (National 
Institute on Drug Abuse Research Report Series, 2000). 
Long term treatment with androstenedione has been 
shown to have negative effects on the cardiovascular 
system. For example, serum high-density lipoprotein 
cholesterol levels in males were decreased following long 
term (8-12 weeks) treatment with androstenedione (King 
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et al. 1999). Previous work (Alen and Rahkila 1988, Alen 
et al. 1985, Costill et al. 1984, Haffner et al. 1983, Hurley 
et al. 1984, Kuipers et al. 1991, Peterson and Fahey 
1984) suggests that elevated plasma levels of androgens 
are associated with an increased risk of cardiovascular 
disease in males. The influence oflong term treatment 
with androstenedione on serum cholesterol levels in 
females is not known. 
Cortisol stimulates gluconeogenesis by the liver, 
mobilizes amino acids from nonhepatic tissues, and 
mobilizes fatty acids from adipose tissues, enabling the 
body to resist stress. Previous studies have demon-
strated an acute increase in plasma cortisol levels fol-
lowing exercise (Chandler et al. 1994, Hakkinen and 
Pakarinen 1993, Kraemer et al. 1993). The potential for 
supplemental androstenedione to enhance cortisol lev-
els during stressful situations, and thus enable the body 
to cope more efficiency with the stressor, has not been 
investigated. 
The increased bone turnover in postmenopausal 
women has been associated with decreased plasma lev-
els of estrogen (Christiansen et al. 1982). There is 
evidence that plasma levels of androstenedione and 
testosterone are greater in premenopausal women com-
pared with both peri- and postmenopausal women (Judd 
and Fournet 1994), and in postmenopausal women a 
positive relationship has been observed between oestra-
diol and testosterone levels and bone mineral density 
(Murphy et al. 1992). Moreover, androstenedione has 
been shown to protect against the development of 
osteopenia in ovariectomized rats, mediating its effect 
through androgen synthesis (Lea and Flanagan 1998). 
The potential role, however, of supplemental andro-
stenedione in the development of peak bone density has 
not been investigated. 
The purpose of this study was to examine the influ-
ence of long-term (10 weeks) treatment with andro-
stenedione on plasma testosterone, cortisol, and choles-
terol, mean arterial pressure (MAP), bone mineral den-
sity (BMD), body weight, and organ weights in female 
rats. Body weight was measured as an index of growth, 
and selected organs were weighed as indices of the 
potential influence oflong term androstenedione treat-
ment on the physiology of these organs. The hypotheses 
ofthis study were as follows: 1) long-term administra-
tion of the supplement androstenedione will have no 
influence on plasma levels of testosterone or cholesterol 
in sedentary female Long Evans rats at rest; 2) long-
term administration of the supplement androstenedi-
one will have no influence on plasma levels of cortisol in 
sedentary female Long Evans rats at rest or during 
exposure to novel immersion stress; 3) long-term admin-
istration of the supplement androstenedione will have 
no influence on the MAP of sedentary female Long 
Evans rats at rest or during exposure to novel immersion 
stress; 4) long-term administration of the supplement 
androstenedione will have no influence on the BMD of 
sedentary female Long Evans rats; 5) long-term admin-
istration of the supplement androstenedione will have 
no influence on the growth (as measured by increase in 
body weight) of sedentary female Long Evans rats; and 
6) long-term administration of the supplement andros-
tenedione will have no influence on the weight of the 
heart, liver, kidneys, adrenal glands, or ovaries of sed en-
tary female Long Evans rats. 
METHODS 
All methods were approved by the University of 
Nebraska at Kearney (UNK) Institutional Animal Care 
and Use Committee. Twenty-six female Long Evans 
rats (originally derived from Charles River stock) born 
between 06/04/99 and 06112199 in the UNK Copeland 
Hall animalfacility were used in this study. At approxi-
mately 10 weeks of age, the rats were anesthetized with 
a mixture of ketamine (100 mg/kg i.p.; K-2753, Sigma 
Chemical Company, St. Louis, MO) and xylazine (20 mg/ 
kg i.p.; X-1251, Sigma Chemical Company, St. Louis, 
MO) for measure of bone mineral density. Bone mineral 
density (BMD) was measured by dual energy x-ray 
absorptiometry(DPX-IQ®, LUNAR®Corporation, Madi-
son, WI) using the forearm acquisition mode in the UNK 
Human Performance Laboratory. While the rats were 
still anesthetized, two, l-cm pieces of Alliedsil® silicone 
tubing (I.D. 0.078"; Allied Biomedical, Paso Robles, CA) 
were implanted in the subcutaneous region between the 
scapulae. In halfthe rats (the androstenedione group, n 
= 13), the silicone tubing contained 100 mg andro-
stenedione plus filler (99.5% purity, ratio to filler 1:10; 
Ultimate Nutrition®, Inc., Farmington, CT) which de-
livered approximately 1 f..lg androstenedione per gram 
body weight per day for 8 weeks. The delivery rate was 
calculated based on the manufacturer's recommended 
daily dosage of androstenedione for adult humans. The 
ends of the silicone tubing were secured with a small 
piece of a wooden dowel and medical implant grade RTV 
adhesive (Applied Silicone Corp., Ventura, CA). The 
remaining rats (the control group, n = 13) were im-
planted with two, 1 cm pieces of silicone tubing which 
contained an equal quantity of dextrose. The rats were 
maintained on normal Purina rat chow and water ad 
libitum and weighed weekly. 
Eight weeks following implantation of the silicone 
tubing, animals were anesthetized as previously de-
scribed and the left femoral artery was exposed. A 
catheter, constructed from a 6 cm piece ofTeflon®tubing 
(I.D. 0.015"; Small Parts, Inc., Miami, FL) inserted into 
a 25 cm piece ofTygon® tubing (I.D. 0.02"; Cole-Parmer, 
Vernon Hills, IL), was placed in the femoral artery. The 
catheter was secured to the artery with 3-0 silk ties, 
tunneled dorsally beneath the animal's skin, exited at 
the base of its neck, and secured with a surgical tether 
button (Harvard Apparatus, Holliston, MA). Following 
surgery, the animal was returned to its home cage, given 
normal rat chow and water ad libitum, and weighed 
daily. All animals were given 2 days to recover from 
surgery. 
Following recovery from surgery, the animals re-
mained in their home cages for a 30 minute measure-
ment of resting mean arterial pressure (MAP) via a 
computerized data acquisition system (MacLab®, CB 
Sciences, Inc., Milford, MA). At the end of the 30 minute 
period, a 2.5 ml blood sample was slowly withdrawn 
from the arterial catheter and placed in a chilled 
microfuge tube containing 10 JlI EDTA (90 mg/ml 
ethyleneglycol-bis[~-animoethyl ether] N,N,N",N"-
tetraacetic acid, Sigma No. E-4378). The sample was 
centrifuged for 5 minutes at 2500 rpm, and the plasma 
was transferred to a clean microfuge tube and stored at 
-80 ·C. The formed elements of the blood were resus-
pended in heparinized isotonic saline (67 USP units/ml) 
to a volume equaling 2.5 ml and returned to the animal. 
The following day the animals were exposed to a 
novel, mild, physical stress, which consisted of being 
placed in a plastic 5-gallon bucket containing shoulder-
deep 37 ·C water for 15 minutes. MAP was measured as 
previously described for 15 minutes before the stress 
while the animal remained in its home cage, during the 
immersion stress, and for 15 minutes immediately after 
the stress when the animal was returned to its home 
cage. A 0.5 ml blood sample was taken before, immedi-
ately after, and 15 minutes after exposure to the immer-
sion stress. The volume of the blood sample was imme-
diately replaced with isotonic saline. The blood samples 
were treated as previously described, except that the 
formed elements of the blood were not returned to the 
animal. 
The following day the animals were euthanized with 
an overdose of ether and the carcasses stored at -80 ·C. 
Following collection of cardiovascular data and plasma 
samples from all animals, the carcasses were thawed 
and a second measure of BMD was made as previously 
described. In addition, the heart, liver, kidneys, adrenal 
glands, and ovaries were excised and weighed. 
Plasma cholesterol was measured using an enzy-
matic, colorimetric assay (procedure 352, Sigma Diag-
nostics, St. Louis, MO). Plasma cortisol and testoster-
one were measured using radioimmunoassay (proce-
dures 07-121002 and 07-189002, respectively, ICN 
Biochemicals, Inc., Costa Mesa, CA). All samples for 
each particular assay were processed simultaneously. 
Bone mineral density was analyzed by highlighting 
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the skull of the rat and selecting the "total" measure of 
BMD for the region. Cardiovascular data were analyzed 
by ANOVA with statistical significance ascribed for p < 
0.05. Body weights, organ weights, BMD, and plasma 
cholesterol, cortisol, and testosterone were analyzed 
using a two-tailed, unpaired t-test with statistical sig-
nificance ascribed for p < 0.05. 
RESULTS 
There were no significant differences in body weight 
between the control group and the androstenedione 
group at any time during the study (Fig. 1). In addition, 
there were no significant differences in MAP between 
the control group and the androstenedione group during 
rest (Fig. 2) or during the stress session (Fig. 3). MAP 
was significantly elevated from rest within both groups 
during the immersion stress and throughout the recov-
ery period, but there were no MAP differences within 
either group between the stress and recovery periods 
(Fig. 3). Plasma cortisol levels were not significantly 
different between groups during any of the sampling 
periods, although plasma cortisol was significantly el-
evated during the recovery period compared to the pre-
stress period within the control group (Fig. 4). 
There were no significant differences in organ weights 
or BMD between groups (Table 1), although BMD was 
significantly higher at the end of the study in both 
groups. Moreover, there was no significant difference in 
plasma testosterone at rest between groups (Table 1). 
Plasma cholesterol (total), however, was significantly 
lower in animals in the androstenedione group com-
pared to animals in the control group (Table 1). 
DISCUSSION 
The major limitation of this study was that circulat-
ing levels of androstenedione were not evaluated, so any 
conclusions about the potential influence of andro-
stenedione on the parameters in question are suspect. 
Plasma androstenedione can be measured using radio-
immunoassay, but, unlike the radioimmunoassay pro-
cedures for measurement of testosterone and cortisol 
which utilize 3H, the procedure for measurement of 
androstenedione utilizes 1251. Data concerning circulat-
ing levels of androstenedione would, of course, permit 
conclusions to be based on the potential influence of 
androstenedione. The primary investigator's institu-
tion is not licensed to use this isotope, so evaluation of 
circulating levels of androstenedione was not possible. 
It is entirely possible that the implants became encased 
with subcutaneous fat or, for some other reason, failed to 
deliver androstenedione at the desired dosage (or at all). 
Moreover, since the animals were not ovariectomized, it 
is also possible that any increase in plasma andro-
stenedione was offset by a decrease in ovarian activity. 
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Figure 1. Weekly body weights offemale Long Evans rats. Rats in the andro group (n = 13) were treated with androstenedione 
(surgical implant to deliver 111g androstenedione per gram body weight daily for 8 weeks) whereas animals in the control group 
(n = 13) were treated with dextrose. Week 1 represents weight on day implant was surgically put in place. Values expressed as 
mean ± standard deviation. 
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Figure 2. Mean arterial pressure offemale Long Evans rats during a 30 minute home cage rest session. Rats in the andro group 
(n = 13) we11! treated with androstenedione (surgical implant to deliver 111g androstenedione per gram body weight daily for 8 
weeks) whereas animals in the control group (n = 10) were treated with dextrose. Values expressed as mean ± standard deviation. 
Therefore, plasma androstenedione levels may have not 
been different between groups. 
The only significant difference observed between 
groups was the lower level of total plasma cholesterol in 
the androstenedione group. This is consistent with the 
general observations of other investigators (King et al. 
1999), who demonstrated that long term treatment with 
androstenedione lowered serum high-density lipopro-
tein cholesterol levels. Again, due to limitations in the 
resources available to the primary investigator, only 
total plasma cholesterol and not the lipoprotein profile of 
these animals was measured in this study. If the lower 
total plasma cholesterol level reflects a decrease in low-
density or very-low density lipoprotein cholesterol lev-
els, this would suggest that the treatment was beneficial 
to the cardiovascular system. If the lower total plasma 
cholesterol level reflects a decrease in high-density lipo-
protein cholesterol levels, however, then the treatment 
would be considered to be potentially deleterious to the 
cardiovascular system. 
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The results of this study demonstrated no influence 
on the cardiovascular activity in sedentary female Long 
Evans rats at rest or during exposure to novel stress. 
While testosterone may have a direct role in the in-
creased risk of cardiovascular disease observed in males 
(Adams et al. 1995, Bruck at al. 1997), short-term 
administration of testosterone has been shown to have 
relaxing effects on coronary arteries in both animals 
(Chou et al. 1996, Yue et al. 1995) and humans (Webb et 
al. 1999). Again due to the limitations of the study, it is 
not possible to conclude that long-term administration 
of androstenedione influences cardiovascular activity. 
There were no differences in plasma levels of test-
osterone and cortisol between groups in this study. King 
et al. (1999) and Wallace et al. (1999) reported no 
increases in plasma levels of testosterone in response to 
acute ingestion of androstenedione. While significant 
increases in serum estradiol and estrone levels have 
been observed following long-term (8 weeks) andro-
stenedione supplementation (King et al. 1999), no in-
creases in serum testosterone were observed. While no 
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Figure 3. Mean arterial pressure offemale Long Evans rats during a novel stress (15-minutes immersion in shoulder-deep 37°C 
water) session. Rats in the andro group (n = 13) were treated with androstenedione (surgical implant to deliver 1 IJ.g 
androstenedione per gram body weight daily for 8 weeks) whereas animals in the control group (n = 10) were treated with dextrose. 
Minutes 5-15 represent a 15 minute home cage pre-stress period, minutes 20-30 represent the 15 minute stress period, and 
minutes 35-45 represent a 15 minute home cage recovery period. Values expressed as mean ± standard deviation. *Significantly 
different from pre-stress period within group, p < 0.05. 
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previous work has been done examining the influence of 
long-term treatment with androstenedione on plasma 
cortisol levels, the limitations ofthe present study do not 
permit any conclusions on the influence of andro-
stenedione supplementation on plasma cortisol levels. 
There were no differences in body weight between 
groups in this study. While this observation is relatively 
consistent with the results of other investigators (King 
et a1. 1999, Wallace et a1. 1999) who reported that long 
term androstenedione supplementation failed to en-
hance lean body mass in males, the limitations of the 
study do not permit any conclusions about the influence 
of androstenedione on either body composition or growth 
in female subjects. In addition, there were no differences 
in organ weights between groups. Long term anabolic 
steroid use is associated with hypertrophy of the heart 
and atrophy of the gonads (National Institute on Drug 
Abuse Research Report Series, 2000), and the liver and 
kidneys must metabolize and excrete waste products, 
respectively, from supplemental steroids. Again, due to 
the limitations of this study, no conclusions about the 
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influence of supplemental androstenedione on organ 
function are possible. 
Bone mineral density was significantly greater in 
both groups at the conclusion ofthe study compared with 
the beginning of the study, but the animals were only 10 
weeks of age at the beginning of the study, so this 
increase in BMD is consistent with the normal changes 
in BMD associated with growth. While previous work 
suggests that supplemental androstenedione can pro-
tect against osteopenia (Lea and Flanagan 1998) and 
that postmenopausal women with higher androgen lev-
els have greater bone mass (Murphy et a1. 1992), the 
results of this study do not indicate any influence on 
peak bone mass development. 
In summary, the inability to measure circulating 
levels of androstenedione in both groups of animals 
severely impacts the ability to make any conclusions 
concerning the influence of long term androstenedione 
treatment on plasma testosterone, cortisol, and choles-
terol, MAP, BMD, body weight, and organ weights in 
* 
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Recovery 
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Andro 
Figure 4. Plasma cortisol levels offemale Long Evans rats exposed to a novel stress (15-minutes immersion in shoulder-deep 37°C 
water) session. Rats in the andro group (n = 13) were treated with androstenedione (surgical implant to deliver 1 ~g 
androstenedione per gram body weight daily for 8 weeks) whereas animals in the control group (n = 10) were treated with dextrose. 
Plasma samples were taken following a 15 minute home cage pre-stress period, following the 15 minute stress period, and 
following a 15 minute home cage recovery period. Values expressed as mean ± standard deviation. *Significantly different from 
pre-stress, p < 0.05. 
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Table 1. Body weight at time of surgery, organ weights, bone mineral density (BMD), and resting levels of plasma testosterone 
and cholesterol of female Long Evans rats. Rats in the androstenedione group (n = 13) were treated with androstenedione 
(surgical implant to deliver 1 J.l.g androstenedione per gram body weight daily for 8 weeks) whereas animals in the control group 
(n = 13 except for plasma data where n = 10) were treated with dextrose. Values are expressed as mean ± standard deviation. 
Androstenedione group Control group 
Body weight (g) at surgery 315.9±24.9 309.8± 21.0 
Heart (whole) (mg) 871± 80 879± 88 
Liver (g) 11.978 ± 0.686 11.763 ± 1.777 
Kidneys (g) 2.339 ± 0.172 2.352 ± 0.297 
Adrenal glands (mg) 92± 13 83± 14 
Ovaries (mg) 85±20 87± 19 
BMD (initial) (g/cm2) 0.314 ± 0.032 0.315 ± 0.025 
BMD (final) (g/cm2) 0.378 ± 0.035# 0.364 ± 0.031# 
Plasma testosterone (ng/ml) 0.0851 ± 0.0150 0.0836 ± 0.0085 
Plasma cholesterol (total; mg/dl) 78.1 ± 52.4 141.9 ± 89.5* 
* Statistically different from androstenedione group, p < 0.05. 
# Statistically different from initial BMD measure, p < 0.05. 
female rats. Given that most of the information concern-
ing the effects oflong term androstenedione treatment 
focus on the influence of this supplement on male sub-
jects, further investigation of the effects of andro-
stenedione on female subjects is warranted. 
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